Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute, part of the National Institutes of Health, to investigate the molecular mechanisms by which ...

Clinical Outcomes of Patients With B-Cell Non-Hodgkin Lymphoma in Real-World Settings: Findings From the Hemato-Oncology Latin America Observational Registry Study In the Thabatse Cancer Cohort, ...

Researchers created a germ-free mouse model to evaluate the role of the microbiome in the infection, replication, and pathogenesis of HIV and the Epstein-Barr virus, the virus that can cause ...

Antiretroviral therapy has decreased the risk of lymphoma in the HIV-positive patient population, yet the incidence is still approximately 70-times greater than the incidence in the noninfected ...

Preliminary clinical data from patients with relapsed/refractory EBV + peripheral T-cell lymphoma in the pivotal NAVAL-1 trial demonstrated overall and complete response rates of 40%; follow-up from ...

-New combined Stage 1 and Stage 2 results from the relapsed or refractory EBV-positive peripheral T-cell lymphoma (PTCL) cohort of the Phase 2 NAVAL-1 trial further demonstrate Nana-val’s substantial ...

—A new study from Switzerland suggests that post-transplant lymphoproliferative disorders (PTLDs) may represent clonal expansions driven by exogenic immunosuppression, Epstein-Barr virus (EBV) ...

SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious ...

Francesca has an MSci in Biochemistry from the University of Birmingham.View full profile Francesca has an MSci in Biochemistry from the University of Birmingham. Epstein-Barr Virus (EBV) is very ...

CHAPEL HILL, N.C. – Over the past decade, the gut microbiome has gained significant interest by scientists and non-scientists alike. Recent research has shown that the bacteria and other microbes in ...